TNG Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.…
Industry Peers
BiotechnologyKey Statistics
About Transgene (EPA: TNG)
›
Transgene (EPA: TNG) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 152 employees.
The shares were at 0.6920 EUR on 19 November 2026, down 45.1% over 52 weeks. Its 52-week range is 0.6700 EUR to 1.365 EUR: the price is 49.3% below the high and 3.3% above the low.
Its market capitalisation is 192.55M EUR.
Transgene reports return on equity of -30.8% and revenue down 34.6% year over year.
It holds more cash than debt, a net cash position of 90.66M EUR. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 1.100 EUR is 59.0% above the current price.